Interventions for Treating Intrahepatic Cholestasis in People with Sickle Cell Disease

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2017 Aug 1

PMID 28759700

Citations 6

Authors

Arturo J Marti-Carvajal

Cristina Elena Marti-Amarista

Affiliations

Soon will be listed here.

Abstract

Background: Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease. This is an update of a previously published Cochrane Review.

Objectives: To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Search Methods: We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 23 May 2017), the WHO International Clinical Trials Registry Platform Search Portal (23 May 2017) and ClinicalTrials.gov.Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 12 April 2017.

Selection Criteria: We searched for published or unpublished randomised controlled trials.

Data Collection And Analysis: Each author intended to independently extract data and assess the risk of bias of the trials by standard Cochrane methodologies; however, no trials were included in the review.

Main Results: There were no randomised controlled trials identified.

Authors' Conclusions: This updated Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.

Citing Articles

Unrecognized hemoglobin SC sickle cell disease complicated by sepsis and cholestasis.

McFarland T, Spillane D, Chernetsova E, Dasgupta K CMAJ. 2022; 194(17):E608-E611.

PMID: 35500915 PMC: 9067383. DOI: 10.1503/cmaj.210981.

Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion.

Adkins B, Savani B, Booth G Clin Hematol Int. 2021; 1(3):127-133.

PMID: 34595422 PMC: 8432363. DOI: 10.2991/chi.d.190630.001.

CD62P (P-selectin) expression as a platelet activation marker in patients with liver cirrhosis with and without cholestasis.

Hegazy S, Elsabaawy M, Eltabakh M, Hammad R, Bedair H Clin Exp Hepatol. 2021; 7(2):231-240.

PMID: 34295992 PMC: 8284161. DOI: 10.5114/ceh.2021.107566.

Dengue fever as a potential cause of sickle cell intrahepatic cholestasis: A report of two cases.

Rodrigues de Oliveira L, Costa A, Almeida P, Zago L, Silva V, Soares-Silva S Rev Soc Bras Med Trop. 2021; 54:e00102021.

PMID: 34259758 PMC: 8282252. DOI: 10.1590/0037-8682-0010-2021.

Acute Liver Failure From Sickle Cell Hepatopathy Treated With Exchange Transfusion.

Kassem A, Park C, Rajkumar A Cureus. 2021; 13(5):e15334.

PMID: 34235013 PMC: 8240763. DOI: 10.7759/cureus.15334.

References

Ware R, De Montalembert M, Tshilolo L, Abboud M . Sickle cell disease. Lancet. 2017; 390(10091):311-323. DOI: 10.1016/S0140-6736(17)30193-9. View

Modell B, Darlison M . Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008; 86(6):480-7. PMC: 2647473. DOI: 10.2471/blt.06.036673. View

Thorlund K, Anema A, Mills E . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clin Epidemiol. 2010; 2:57-66. PMC: 2943189. DOI: 10.2147/clep.s9242. View

Khurshid I, Anderson L, Downie G, Pape G . Sickle cell disease, extreme hyperbilirubinemia, and pericardial tamponade: case report and review of the literature. Crit Care Med. 2002; 30(10):2363-7. DOI: 10.1097/00003246-200210000-00029. View

Yawn B, Buchanan G, Afenyi-Annan A, Ballas S, Hassell K, James A . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-48. DOI: 10.1001/jama.2014.10517. View

SHEEHY T, Law D, Wade B . Exchange transfusion for sickle cell intrahepatic cholestasis. Arch Intern Med. 1980; 140(10):1364-6. View

Ebert E, Nagar M, Hagspiel K . Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol. 2010; 8(6):483-9. DOI: 10.1016/j.cgh.2010.02.016. View

Ioannidis J . Meta-research: The art of getting it wrong. Res Synth Methods. 2015; 1(3-4):169-84. DOI: 10.1002/jrsm.19. View

OCallaghan A, OBrien S, Ninkovic M, Butcher G, Foster C, Walters J . Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Gut. 1995; 37(1):144-7. PMC: 1382787. DOI: 10.1136/gut.37.1.144. View

10.

Baichi M, Arifuddin R, Mantry P, Bozorgzadeh A, Ryan C . Liver transplantation in sickle cell anemia: a case of acute sickle cell intrahepatic cholestasis and a case of sclerosing cholangitis. Transplantation. 2005; 80(11):1630-2. DOI: 10.1097/01.tp.0000184446.52454.69. View

11.

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

12.

Horn A, Freed N, Pecora A . Sickle cell hepatopathy: diagnosis and treatment with exchange transfusion. J Am Osteopath Assoc. 1987; 87(2):130-3. View

13.

Guyatt G, Oxman A, Kunz R, Atkins D, Brozek J, Vist G . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011; 64(4):395-400. DOI: 10.1016/j.jclinepi.2010.09.012. View

14.

Kato G, Gladwin M . Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA. 2008; 300(22):2638-46. PMC: 2756016. DOI: 10.1001/jama.2008.598. View

15.

Gluud C . "Negative trials" are positive!. J Hepatol. 1998; 28(4):731-3. DOI: 10.1016/s0168-8278(98)80301-2. View

16.

Guyatt G, Oxman A, Sultan S, Brozek J, Glasziou P, Alonso-Coello P . GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2012; 66(2):151-7. DOI: 10.1016/j.jclinepi.2012.01.006. View

17.

Kaplan A . Complications of apheresis. Semin Dial. 2012; 25(2):152-8. DOI: 10.1111/j.1525-139X.2011.01026.x. View

18.

Ballas S, Kesen M, Goldberg M, Lutty G, Dampier C, Osunkwo I . Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. 2012; 2012:949535. PMC: 3415156. DOI: 10.1100/2012/949535. View

19.

Akinsheye I, Klings E . Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol. 2010; 224(3):620-5. DOI: 10.1002/jcp.22195. View

20.

Omata M, Johnson C, Tong M, TATTER D . Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci. 1986; 31(3):247-56. DOI: 10.1007/BF01318115. View